Headquartered in Austin, Texas, Mati Therapeutics is developing a non-invasive sustained drug delivery platform to treat ocular diseases, in particular glaucoma.
More than 1 billion people worldwide have vision impairment or blindness from potentially preventable or correctable causes Vision impairment is associated with a lower quality of life and many other co-morbidities such as depression, anxiety, and cognitive decline there is an expressed need to help patients treat their ocular disorder. Mati has developed the Evolute® Punctal Plug Delivery System to address the need to improve outcomes in ocular disease. The Evolute® is a small, comfortable and cosmetically invisible device that automatically delivers the required medication to the patient for an extended period of time eliminating the need for patients or care givers to administer eye drops.
The founders of Mati held senior leadership positions at Allergan, AMO, Abbott Laboratories and QLT Inc. With over hundred years of experience in ophthalmology they are well versed and dedicated to delivering sustained therapy delivery in ophthalmology to treat multiple ophthalmic disorders.